Compare WEAV & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | MPLT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.2M | 594.8M |
| IPO Year | 2021 | 2025 |
| Metric | WEAV | MPLT |
|---|---|---|
| Price | $6.75 | $20.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $12.20 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 1.5M | 260.1K |
| Earning Date | 10-30-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,790,000.00 | N/A |
| Revenue This Year | $19.19 | N/A |
| Revenue Next Year | $15.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | N/A |
| 52 Week Low | $5.64 | $12.24 |
| 52 Week High | $17.63 | $21.00 |
| Indicator | WEAV | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | N/A |
| Support Level | $6.23 | N/A |
| Resistance Level | $6.61 | N/A |
| Average True Range (ATR) | 0.22 | 0.00 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 95.02 | 0.00 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.